Asahi Kasei firm Zoll acquire Kyma Medical Technologies

Asahi Kasei firm Zoll to acquire Kyma Medical Technologies

10:56 AM, 18th September 2015
Asahi Kasei firm Zoll to acquire Kyma Medical Technologies

CHELMSFORD, US: Zoll Medical Corporation, an Asahi Kasei Group company that manufactures medical devices and related software solutions, said that it has acquired Tel Aviv, Israel-based Kyma Medical Technologies Ltd, which develops technologies to measure early signs of congestive heart failure.

In January 2015, Kyma had received CE mark approval for the µ Cor system for monitoring thoracic fluid content, ECG, heart rate, respiration rate, activity and posture.

Zoll plans to maintain Kyma’s facilities and workforce in Israel and California as a part of Zoll’s Lifevest division.

Kyma is developing the remote patient monitoring system for fluid management in a variety of patients including those suffering from heart failure. This µ-Cor system uses radio frequency-based technology to monitor the level of fluid in the lungs. It also collects data on heart rate, respiration rate, activity, and posture, all of which are analyzed using proprietary algorithms to determine patient-specific vital signs trends. Once a potential deterioration in the patient’s condition is identified, a notification is sent to the patient’s medical team.

“The acquisition of Kyma Medical will allow Zoll to broaden its product offerings with additional technologies designed to improve outcomes for heart failure patients with fluid management problems, with the goal of reducing hospitalizations,” said Jason Whiting, president of Zoll Lifevest.

“With the acquisition, Kyma’s technology will be able to better reach global markets through ZOLL’s existing network. Additionally, we expect to leverage Kyma’s strong R&D capabilities as well as the broader research talent available in Israel,” he added.

“Zoll provides Kyma with an increased infrastructure of clinical and commercial resources that will enable our technology to reach a greater number of clinicians and patients,” said Murali Srivathsa, president & CEO, Kyma.

“The strategic and cultural fit between Zoll and Kyma represents the best opportunity to bring Kyma’s innovative technologies to patients worldwide,” said Guy Katsav, chairman, Kyma.

© Worldofchemicals News



Your Comments (Up to 2000 characters)
Please respect our community and the integrity of its participants. WOC reserves the right to moderate and approve your comment.

Related News

Trinseo to close Connecticut latex plant; expects to lay off 17 employees

BERWYN, US: Trinseo SA said it plans to close its styrene butadiene latex plant in Gales Ferry, Connecticut, due to continuing declines in the coated ...

Read more
US majors Johnson & Johnson and Hilliard Energy to invest in India

BANGALORE, INDIA: As India’s prime minister Narendra Modi, prepares to make his second big pitch to attract investment from US companies, he wil ...

Read more
CP Kelco plans to expand biogums capacity

ATLANTA, US: In response to the strong global demand for specialty biogums products, CP Kelco US Inc said it plans to invest in building three bi ...

Read more
Air Products to spin-off materials technologies business

LEHIGH VALLEY, US: Air Products and Chemicals Inc said that it intends to fully separate its materials technologies business via a tax-free spin- ...

Read more
Inovyn to close PVC production site in Germany

LONDON, UK: PVC producer Inovyn Chlorvinyls Ltd, a 50-50 JV of chlorvinyls activities of Ineos and Solvay, said that its PVC production facility at Sc ...

Read more
FDA warns companies in India and New Zealand for cGMP violations

MARYLAND, US: US Food and Drug Administration (FDA) issued a warning letter to a company in India and New Zealand citing violations of current good ma ...

Read more uses cookies to ensure that we give you the best experience on our website. By using this site, you agree to our Privacy Policy and our Terms of Use. X